MileBot Robotics, a Shenzhen exoskeleton robot provider, said it has closed a new strategic round near 100 million yuan from state backed CSC Financial. The funds accelerate product iteration and the rollout of brain computer interface and other frontier tech, covering the last mile from hospital to community to home in care scenarios.
Earlier backers already read like a who’s who: Lenovo Capital, which has now invested four rounds, plus Taiyou Fund, Sihuan Pharma, Star Fund, Dening Industrial and Shangshan Capital.
MileBot was founded in 2016 by a returnee PhD team as a provider of medical and care exoskeleton products and solutions. Its new CEO Chen Kangning previously worked at Johnson and Johnson and similar multinationals, with deep experience in product registration, launch and channel building, a fit for scaled, market driven growth.
Since founding, MileBot has focused on flexible actuator human interaction tech and built a broad matrix: the H series, A series, C series children’s lower limb rehab, the 3,000 Steps care range and the Max daily walking aid, covering in hospital rehab, home care and daily walking.
The 3,000 Steps care range breaks the single scene limit of traditional walking exercise with light, portable, human centred design, fitting hospital, community, park and home, helping users build a daily 3,000 step habit and lowering the care exercise barrier.
The company holds over 200 patents, and core products have NMPA Class II certification and are in volume market use. In 2025 its revenue grew nearly 200 per cent, with overseas contributing over a third.
The sector is heating fast. Many call 2025 the breakout year for exoskeletons. Once niche and high barrier, the devices are quickly entering consumer and care markets. Per IDC, China’s exoskeleton market passed 1.6 billion yuan in 2025 with about 26,000 units shipped. Medical rehab led value, but consumer assist drove volume at over 70 per cent of shipments.
In 2026 the heat rose further. Commerce Ministry data shows first half smart exoskeleton device demand up 458.4 per cent year on year, and JD retail data shows product transactions up over 15,000 per cent, demand unlocked.
Policy adds tailwind. The national medical insurance plan for the 15th five year period explicitly promotes smart exoskeletons in long term care. Policy, market and consumer dividends together are pushing exoskeletons from niche tech to care necessity, and the growth potential keeps releasing.
Editor’s note: This is an adapted translation of the original OFweek report. It has been trimmed and restructured for readability for an international business audience. The full original (in Chinese) is at https://robot.ofweek.com/2026-08/ART-8321203-8120-30700672.html.